About: Mood, anxiety and olfactory dysfunction in COVID‐19: evidence of central nervous system involvement?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mood, anxiety and olfactory dysfunction in COVID‐19: evidence of central nervous system involvement? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Mood, anxiety and olfactory dysfunction in COVID‐19: evidence of central nervous system involvement?
Creator	Brockmeier, Steffi Gengler, Isabelle Oberle, Michael Sedaghat, Ahmad Singer-Cornelius, Thirza Speth, Marlene
Source	Medline; PMC
abstract	INTRODUCTION: The objective of this study was to determine the burden of depressed mood and anxiety in COVID‐19, and associated disease characteristics. MATERIALS AND METHODS: This is a prospective, cross‐sectional study of 114 COVID‐19 positive patients diagnosed using RT‐PCR‐based testing over a 6‐week period. The 2‐item Patient Health Questionnaire (PHQ‐2) and the 2‐item Generalized Anxiety Disorder questionnaire (GAD‐2) were used to measure depressed mood and anxiety level, respectively, at enrollment and for participants’ baseline, pre‐COVID‐19 state. Severity of smell loss, loss of taste, nasal obstruction, rhinorrhea/mucus production, fever, cough and shortness of breath (SOB) during COVID‐19 were assessed. RESULTS: PHQ‐2 and GAD‐2 significantly (p<0.001) increased from baseline to enrollment. PHQ‐2 was associated with smell loss (adjusted incidence rate ratio [aIRR]=1.40, 95%CI: 1.10‐1.78, p=0.006), age (aIRR=1.02, 95%CI: 1.01‐1.04, p=0.006), and baseline PHQ‐2 score (aIRR=1.39, 95%CI: 1.09‐1.76, p=0.007). GAD‐2 score was associated with smell loss (aIRR=1.29, 95%CI: 1.02‐1.62, p=0.035), age (aIRR=1.02, 95%CI: 1.01‐1.04, p=0.025) and baseline GAD‐2 score (aIRR=1.55, 95%CI: 1.24‐1.93, p<0.001). Loss of taste also exhibited similar associations with PHQ‐2 and GAD‐2. PHQ‐2 and GAD‐2 scores were not associated with severities of any other symptoms during the COVID‐19 course. CONCLUSIONS: Despite the occurrence of symptoms—such as SOB—associated with severe manifestations of COVID‐19, only the severities of smell and taste loss were associated with depressed mood and anxiety. These results may raise the novel possibility of emotional disturbance as a CNS manifestation of COVID‐19 given trans‐olfactory tract penetration of the central nervous system (CNS) by coronaviruses.
has issue date	2020-07-02(xsd:dateTime)
bibo:doi	10.1002/lary.28964
bibo:pmid	32617983
has license	no-cc
sha1sum (hex)	8a94d5604fa458cdcfee691b097a4b226262c6e2
schema:url	https://doi.org/10.1002/lary.28964
resource representing a document's title	Mood, anxiety and olfactory dysfunction in COVID‐19: evidence of central nervous system involvement?
has PubMed Central identifier	PMC7361512
has PubMed identifier	32617983
schema:publication	Laryngoscope
resource representing a document's body	covid:8a94d5604fa458cdcfee691b097a4b226262c6e2#body_text
is schema:about of	named entity 'BURDEN' named entity 'COVID-19' named entity 'Mood' named entity 'COVID-19' named entity 'COVID-19' covid:arg/8a94d5604fa458cdcfee691b097a4b226262c6e2 named entity 'depressed mood' named entity 'central nervous' named entity 'anxiety' named entity 'olfactory dysfunction' named entity 'EVIDENCE OF' named entity 'MOOD' named entity 'depressed mood' named entity 'central nervous system' named entity 'OBJECTIVE' named entity 'determine' named entity 'disease' named entity 'study' named entity 'anxiety' named entity 'ASSOCIATED' named entity 'ANXIETY' named entity 'DETERMINE' named entity 'DEPRESSED MOOD' named entity 'COVID-19' named entity 'evidence' named entity 'anxiety' named entity 'olfactory dysfunction' named entity 'DISEASE CHARACTERISTICS' named entity 'COVID-19' named entity 'STUDY' named entity 'ANXIETY' named entity 'COVID-19' named entity 'OLFACTORY DYSFUNCTION' named entity 'CENTRAL NERVOUS SYSTEM INVOLVEMENT' nodeID://b56578590 nodeID://b56595498 nodeID://b56693286 nodeID://b56788534 nodeID://b56814818 nodeID://b56816442 nodeID://b56873002 nodeID://b56916370 nodeID://b56923978 nodeID://b56984862 nodeID://b57183150 nodeID://b57192766 nodeID://b57242978 nodeID://b57326526 nodeID://b57328290 nodeID://b57371058 nodeID://b57408366 nodeID://b57481758 nodeID://b57674402 nodeID://b57744426 nodeID://b57852742 nodeID://b57998274 nodeID://b58006102 nodeID://b58009790 nodeID://b58079198 nodeID://b58120178 nodeID://b58120974
is wasQuotedFrom of	covid:arg/8a94d5604fa458cdcfee691b097a4b226262c6e2/2 covid:arg/8a94d5604fa458cdcfee691b097a4b226262c6e2/3 covid:arg/8a94d5604fa458cdcfee691b097a4b226262c6e2/0 covid:arg/8a94d5604fa458cdcfee691b097a4b226262c6e2/1
is part of of	INTRODUCTION: The objective of this study was to determine the burden of depressed mood and anxiety in COVID‐19, and associated disease characteristics. MATERIALS AND METHODS: This is a prospective, cross‐sectional study of 114 COVID‐19 positive patients diagnosed using RT‐PCR‐based testing over a 6‐week period. The 2‐item Patient Health Questionnaire (PHQ‐2) and the 2‐item Generalized Anxiety Disorder questionnaire (GAD‐2) were used to measure depressed mood and anxiety level, respectively, at enrollment and for participants’ baseline, pre‐COVID‐19 state. Severity of smell loss, loss of taste, nasal obstruction, rhinorrhea/mucus production, fever, cough and shortness of breath (SOB) during COVID‐19 were assessed. RESULTS: PHQ‐2 and GAD‐2 significantly (p<0.001) increased from baseline to enrollment. PHQ‐2 was associated with smell loss (adjusted incidence rate ratio [aIRR]=1.40, 95%CI: 1.10‐1.78, p=0.006), age (aIRR=1.02, 95%CI: 1.01‐1.04, p=0.006), and baseline PHQ‐2 score (aIRR=1.39, 95%CI: 1.09‐1.76, p=0.007). GAD‐2 score was associated with smell loss (aIRR=1.29, 95%CI: 1.02‐1.62, p=0.035), age (aIRR=1.02, 95%CI: 1.01‐1.04, p=0.025) and baseline GAD‐2 score (aIRR=1.55, 95%CI: 1.24‐1.93, p<0.001). Loss of taste also exhibited similar associations with PHQ‐2 and GAD‐2. PHQ‐2 and GAD‐2 scores were not associated with severities of any other symptoms during the COVID‐19 course. CONCLUSIONS: Despite the occurrence of symptoms—such as SOB—associated with severe manifestations of COVID‐19, only the severities of smell and taste loss were associated with depressed mood and anxiety. These results may raise the novel possibility of emotional disturbance as a CNS manifestation of COVID‐19 given trans‐olfactory tract penetration of the central nervous system (CNS) by coronaviruses. Mood, anxiety and olfactory dysfunction in COVID‐19: evidence of central nervous system involvement? covid:8a94d5604fa458cdcfee691b097a4b226262c6e2#body_text

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software